VIRX vs. IPA, DARE, APLM, APRE, ACXP, THTX, NRXP, BCTX, FBIO, and SPRB
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include ImmunoPrecise Antibodies (IPA), Daré Bioscience (DARE), Apollomics (APLM), Aprea Therapeutics (APRE), Acurx Pharmaceuticals (ACXP), Theratechnologies (THTX), NRx Pharmaceuticals (NRXP), BriaCell Therapeutics (BCTX), Fortress Biotech (FBIO), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical preparations" industry.
Viracta Therapeutics (NASDAQ:VIRX) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
Viracta Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.
Viracta Therapeutics received 19 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 72.22% of users gave Viracta Therapeutics an outperform vote.
ImmunoPrecise Antibodies has higher revenue and earnings than Viracta Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viracta Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 764.20%. ImmunoPrecise Antibodies has a consensus target price of $7.00, indicating a potential upside of 483.33%. Given Viracta Therapeutics' higher possible upside, equities analysts clearly believe Viracta Therapeutics is more favorable than ImmunoPrecise Antibodies.
In the previous week, Viracta Therapeutics had 3 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 3 mentions for Viracta Therapeutics and 0 mentions for ImmunoPrecise Antibodies. Viracta Therapeutics' average media sentiment score of 0.00 equaled ImmunoPrecise Antibodies'average media sentiment score.
Viracta Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -60.23%. ImmunoPrecise Antibodies' return on equity of -26.54% beat Viracta Therapeutics' return on equity.
31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Viracta Therapeutics beats ImmunoPrecise Antibodies on 9 of the 15 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viracta Therapeutics Competitors List
Related Companies and Tools
